keyword
MENU ▼
Read by QxMD icon Read
search

prolactin and breast cancer

keyword
https://www.readbyqxmd.com/read/27823949/risk-of-breast-cancer-in-risperidone-users-a-nationwide-cohort-study
#1
Johan Reutfors, Louise Wingård, Lena Brandt, Yiting Wang, Hong Qiu, Helle Kieler, Shahram Bahmanyar
BACKGROUND: Several antipsychotics, especially risperidone, are known to increase serum prolactin. Hyperprolactinemia has been linked to the development of mammary gland tumors in animal studies. We therefore investigated the risk of breast cancer in a nationwide cohort of women using risperidone or other antipsychotics. METHODS: All women, 18years or older, who initiated treatment with risperidone or any other antipsychotic between 2006 and 2012 were identified in Swedish nationwide registers...
November 4, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27782069/what-is-breast-in-the-bone
#2
REVIEW
Carrie S Shemanko, Yingying Cong, Amanda Forsyth
The normal developmental program that prolactin generates in the mammary gland is usurped in the cancerous process and can be used out of its normal cellular context at a site of secondary metastasis. Prolactin is a pleiotropic peptide hormone and cytokine that is secreted from the pituitary gland, as well as from normal and cancerous breast cells. Experimental and epidemiologic data suggest that prolactin is associated with mammary gland development, and also the increased risk of breast tumors and metastatic disease in postmenopausal women...
October 22, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27681435/truncating-prolactin-receptor-mutations-promote-tumor-growth-in-murine-estrogen-receptor-alpha-mammary-carcinomas
#3
Obi L Griffith, Szeman Ruby Chan, Malachi Griffith, Kilannin Krysiak, Zachary L Skidmore, Jasreet Hundal, Julie A Allen, Cora D Arthur, Daniele Runci, Mattia Bugatti, Alexander P Miceli, Heather Schmidt, Lee Trani, Krishna-Latha Kanchi, Christopher A Miller, David E Larson, Robert S Fulton, William Vermi, Richard K Wilson, Robert D Schreiber, Elaine R Mardis
Estrogen receptor alpha-positive (ERα+) luminal tumors are the most frequent subtype of breast cancer. Stat1(-/-) mice develop mammary tumors that closely recapitulate the biological characteristics of this cancer subtype. To identify transforming events that contribute to tumorigenesis, we performed whole genome sequencing of Stat1(-/-) primary mammary tumors and matched normal tissues. This investigation identified somatic truncating mutations affecting the prolactin receptor (PRLR) in all tumor and no normal samples...
September 27, 2016: Cell Reports
https://www.readbyqxmd.com/read/27658959/prolactin-receptor-in-breast-cancer-marker-for-metastatic-risk
#4
Carrie S Shemanko
Prolactin and prolactin receptor signaling and function are complex in nature and intricate in function. Basic, pre-clinical and translational research has opened up our eyes to the understanding that prolactin and prolactin receptor signaling function differently within different cellular contexts and microenvironmental conditions. Its multiple roles in normal physiology are subverted in cancer initiation and progression, and gradually we are teasing out the intricacies of function and therapeutic value. Recently, we observed that prolactin has a role in accelerating the time to bone metastasis in breast cancer patients and identified the mechanism by which prolactin stimulated breast cancer cell-mediated lytic osteoclast formation...
November 2016: Journal of Molecular Endocrinology
https://www.readbyqxmd.com/read/27658833/antipsychotic-treatment-prolactin-and-breast-tumorigenesis
#5
Marc De Hert, Davy Vancampfort, Brendon Stubbs, Tine Sabbe, Hans Wildiers, Johan Detraux
BACKGROUND: Over the last decades prolactin (PRL) has gained attention for its possible role in breast tumorigenesis. As all antipsychotics (although differences with respect to PRL elevation are large) have the propensity to induce hyperprolactinemia (HPRL), questions have arisen concerning the influence of PRL-elevating antipsychotic medications on breast cancer risk. SUBJECTS AND METHODS: A literature search (until January 2016), using the MEDLINE database, was conducted for English-language published clinical studies to identify and synthesize data of the current state of knowledge concerning the relationship between HPRL, breast cancer risk (factors) and antipsychotic medication...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27649560/hormone-receptor-expression-analyses-in-neoplastic-and-non-neoplastic-canine-mammary-tissue-by-a-bead-based-multiplex-branched-dna-assay-a-gene-expression-study-in-fresh-frozen-and-formalin-fixed-paraffin-embedded-samples
#6
Annika Mohr, Florenza Lüder Ripoli, Susanne Conradine Hammer, Saskia Willenbrock, Marion Hewicker-Trautwein, Zdzisław Kiełbowicz, Hugo Murua Escobar, Ingo Nolte
Immunohistochemistry (IHC) is currently considered the method of choice for steroid hormone receptor status evaluation in human breast cancer and, therefore, it is commonly utilized for assessing canine mammary tumors. In case of low hormone receptor expression, IHC is limited and thus is complemented by molecular analyses. In the present study, a multiplex bDNA assay was evaluated as a method for hormone receptor gene expression detection in canine mammary tissues. Estrogen receptor (ESR1), progesterone receptor (PGR), prolactin receptor (PRLR) and growth hormone receptor (GHR) gene expressions were evaluated in neoplastic and non-neoplastic canine mammary tissues...
2016: PloS One
https://www.readbyqxmd.com/read/27639886/-prolactin-antipsychotics-and-breast-cancer-is-there-a-connection
#7
T Sabbe, J Detraux, M De Hert
BACKGROUND: The use of antipsychotics can result in elevated prolactin levels or hyperprolactinemia. An increasing number of studies suggests that prolactin plays a role in mammary carcinogenesis, leading to concerns about a possible relationship between antipsychotics and breast cancer.<br/> AIM: To provide an overview of recent literature regarding the relationship between prolactin, antipsychotics and breast cancer and an association between schizophrenia and breast cancer...
2016: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/27602994/prolactin-inducible-protein-from-breast-cancer-biomarker-to-immune-modulator-novel-insights-from-knockout-mice
#8
Olivia C Ihedioha, Robert P C Shiu, Jude E Uzonna, Yvonne Myal
The propensity for breast cancers to elicit immune responses in patients is well established. The accumulation of tumor infiltrating lymphocytes within the primary breast tumor has been linked to better prognosis and better response to therapy. The prolactin-inducible protein (PIP) is a 15 kD protein that is expressed under physiological conditions of the breast and is regarded as a marker of mammary differentiation. While highly expressed under pathological conditions of the mammary gland, including breast cancers, PIP is expressed in very few other cancers...
October 2016: DNA and Cell Biology
https://www.readbyqxmd.com/read/27575941/gain-of-function-prolactin-receptor-variants-are-not-associated-with-breast-cancer-and-multiple-fibroadenoma-risk
#9
Zeina Chakhtoura, Fatima Laki, Marie Bernadet, Ibtissem Cherifi, Aurélie Chiche, Natascha Pigat, Sophie Bernichtein, Carine Courtillot, Florence Boutillon, Ivan Bièche, Sophie Vacher, Marie-Laure Tanguy, Anne Bissery, Virginie Grouthier, Philippe Camparo, Marc Foretz, Marcio Do Cruzeiro, Rémi Pierre, Fabienne Rakotozafy, Jean Tichet, Isabelle Tejedor, Jacques-Emmanuel Guidotti, Brigitte Sigal-Zafrani, Vincent Goffin, Philippe Touraine
CONTEXT: in a cohort of 95 women with multiple breast fibroadenomas (MFA), we recently identified patients harboring germline heterozygous variants of the prolactin receptor (PRLR) exhibiting constitutive activity (PRLRI146L and PRLRI176V). OBJECTIVE: to better delineate the potential role of PRLR gain-of-function variants in benign and malignant mammary tumorigenesis Design: observational study and transgenic mouse model analysis Setting: Department of Endocrinology, Reproductive Disorders and Rare Gynecologic Diseases, Pitié Salpêtrière, Paris, and Inserm Unit 1151, Paris Patients or Other Participants: we generated a second MFA cohort (n=71) as well as a group of control subjects (n=496) and a cohort of women with breast cancer (BC, n=119)...
August 30, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27564112/role-of-egf-erbb1-in-the-transcriptional-regulation-of-the-prolactin-receptor-independent-of-estrogen-and-prolactin-in-breast-cancer-cells
#10
Raghuveer Kavarthapu, Maria L Dufau
Prolactin receptor (PRLR) and epidermal growth factor receptor (EGFR/ERBB1) have important roles in the physiology of the human breast and in the etiology and progression of breast cancer. Our present studies in MCF-7 cells revealed that EGF induces up-regulation of PRLR via activation of EGFR signalling pathways leading to activation of estrogen receptor α (ERα). EGF treatment of MCF-7 cells cultured in absence of estradiol induced expression of PRLR that was consistent with the activation of PRLR generic promoter (hPIII)...
August 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27542844/prolactin-induced-pak1-tyrosyl-phosphorylation-promotes-fak-dephosphorylation-breast-cancer-cell-motility-invasion-and-metastasis
#11
Alan Hammer, Maria Diakonova
BACKGROUND: The serine/threonine kinase PAK1 is an important regulator of cell motility. Both PAK1 and the hormone/cytokine prolactin (PRL) have been implicated in breast cancer cell motility, however, the exact mechanisms guiding PRL/PAK1 signaling in breast cancer cells have not been fully elucidated. Our lab has previously demonstrated that PRL-activated tyrosine kinase JAK2 phosphorylates PAK1 on tyrosines 153, 201, and 285, and that tyrosyl phosphorylated PAK1 (pTyr-PAK1) augments migration and invasion of breast cancer cells...
2016: BMC Cell Biology
https://www.readbyqxmd.com/read/27489110/identification-of-nek3-kinase-threonine-165-as-a-novel-regulatory-phosphorylation-site-that-modulates-focal-adhesion-remodeling-necessary-for-breast-cancer-cell-migration
#12
Katherine M Harrington, Charles V Clevenger
Accumulating evidence supports a role for prolactin (PRL) in the development and progression of human breast cancer. Although PRL is an established chemoattractant for breast cancer cells, the precise molecular mechanisms of how PRL regulates breast cancer cell motility and invasion are not fully understood. PRL activates the serine/threonine kinase NEK3, which was reported to enhance breast cancer cell migration, invasion, and the actin cytoskeletal reorganization necessary for these processes. However, the specific mechanisms of NEK3 activation in response to PRL signaling have not been defined...
October 7, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27358110/hdac6-deacetylates-hmgn2-to-regulate-stat5a-activity-and-breast-cancer-growth
#13
Terry R Medler, Justin M Craig, Alyson A Fiorillo, Yvonne B Feeney, J Chuck Harrell, Charles V Clevenger
: Stat5a is a transcription factor utilized by several cytokine/hormone receptor signaling pathways that promotes transcription of genes associated with proliferation, differentiation, and survival of cancer cells. However, there are currently no clinically approved therapies that directly target Stat5a, despite ample evidence that it contributes to breast cancer pathogenesis. Here, deacetylation of the Stat5a coactivator and chromatin-remodeling protein HMGN2 on lysine residue K2 by HDAC6 promotes Stat5a-mediated transcription and breast cancer growth...
October 2016: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/27344177/prolactin-signaling-through-focal-adhesion-complexes-is-amplified-by-stiff-extracellular-matrices-in-breast-cancer-cells
#14
Craig E Barcus, Patricia J Keely, Kevin W Eliceiri, Linda A Schuler
Estrogen receptor α positive (ERα+) breast cancer accounts for most breast cancer deaths. Both prolactin (PRL) and extracellular matrix (ECM) stiffness/density have been implicated in metastatic progression of this disease. We previously demonstrated that these factors cooperate to fuel processes involved in cancer progression. Culture of ERα+ breast cancer cells in dense/stiff 3D collagen-I matrices shifts the repertoire of PRL signals, and increases crosstalk between PRL and estrogen to promote proliferation and invasion...
June 17, 2016: Oncotarget
https://www.readbyqxmd.com/read/27293986/prolactin-induced-protein-as-a-potential-therapy-response-marker-of-adjuvant-chemotherapy-in-breast-cancer-patients
#15
Karolina Jablonska, Jedrzej Grzegrzolka, Marzenna Podhorska-Okolow, Mariusz Stasiolek, Bartosz Pula, Mateusz Olbromski, Agnieszka Gomulkiewicz, Aleksandra Piotrowska, Janusz Rys, Aleksandra Ambicka, Siew Hwa Ong, Maciej Zabel, Piotr Dziegiel
Many studies are dedicated to exploring the molecular mechanisms of chemotherapy-resistance in breast cancer (BC). Some of them are focused on searching for candidate genes responsible for this process. The aim of this study was typing the candidate genes associated with the response to standard chemotherapy in the case of invasive ductal carcinoma. Frozen material from 28 biopsies obtained from IDC patients with different responses to chemotherapy were examined using gene expression microarray, Real-Time PCR (RT-PCR) and Western blot (WB)...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27184120/plasma-prolactin-and-breast-cancer-risk-a-meta-analysis
#16
Minghao Wang, Xiujuan Wu, Fan Chai, Yi Zhang, Jun Jiang
Breast cancer is the most common cancer among women, and its incidence is on a constant rise. Previous studies suggest that higher levels of plasma prolactin are associated with escalated risk of breast cancer, however, these results are contradictory and inconclusive. PubMed and Medline were used to search and identify published observational studies that assessed the relationship between plasma prolactin levels and the risk of breast cancer. The pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a fixed-effects or random-effects model...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27176613/prolactin-signaling-stimulates-invasion-via-na-h-exchanger-nhe1-in-t47d-human-breast-cancer-cells
#17
Elena Pedraz-Cuesta, Jacob Fredsted, Helene H Jensen, Annika Bornebusch, Lene N Nejsum, Birthe B Kragelund, Stine F Pedersen
Prolactin (PRL) and its receptor (PRLR) are implicated in breast cancer invasiveness, although their exact roles remain controversial. The Na(+)/H(+) exchanger (NHE1) plays essential roles in cancer cell motility and invasiveness, but the PRLR and NHE1 have not previously been linked. Here we show that in T47D human breast cancer cells, which express high levels of PRLR and NHE1, exposure to PRL led to the activation of Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5), Akt, and ERK1/2 signaling and the rapid formation of peripheral membrane ruffles, known to be associated with cell motility...
July 2016: Molecular Endocrinology
https://www.readbyqxmd.com/read/27165168/antidepressant-use-and-circulating-prolactin-levels
#18
Katherine W Reeves, Olivia I Okereke, Jing Qian, Shelley S Tworoger, Megan S Rice, Susan E Hankinson
PURPOSE: To determine whether antidepressants (AD), specifically selective serotonin reuptake inhibitors (SSRIs), are linked to elevated prolactin levels among the general population. METHODS: Circulating prolactin levels were available for 4593 healthy participants in the Nurses' Health Study (NHS) and NHS2, including 267 AD users. We fit generalized linear models to calculate and compare adjusted mean prolactin levels between AD users and non-users and further among SSRI users...
July 2016: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/27107001/targeting-prolactin-receptor-prlr-signaling-in-prlr-positive-breast-and-prostate-cancer
#19
Ciara C O'Sullivan, Susan E Bates
No abstract text is available yet for this article.
May 2016: Oncologist
https://www.readbyqxmd.com/read/27091421/phase-i-study-of-the-prolactin-receptor-antagonist-lfa102-in-metastatic-breast-and-castration-resistant-prostate-cancer
#20
Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, Nancy Lewis, Michaela Higgins, Kari Wisinski, Ahmad Awada, Michela Maur, Mark Stein, Andy Hwang, Rebecca Mosher, Ernesto Wasserman, Gang Wu, Hefei Zhang, Renata Zieba, Mohamed Elmeliegy
LESSONS LEARNED: Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor-binding monoclonal antibody has not produced clinical efficacy.Increased serum prolactin levels may be a biomarker for prolactin receptor inhibition.Results from the pharmacokinetic and pharmacodynamics (PD) studies suggest that inappropriately long dosing intervals and insufficient exposure to LFA102 may have resulted in lack of antitumor efficacy.Based on preclinical data, combination therapy of LFA102 with those novel agents targeting hormonal pathways in metastatic castration-resistant prostate cancer and metastatic breast cancer is promising...
May 2016: Oncologist
keyword
keyword
71333
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"